Louisiana State Employees Retirement System Takes Position in United Therapeutics Corporation $UTHR

Louisiana State Employees Retirement System bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 1st quarter, according to its most recent filing with the SEC. The firm bought 12,500 shares of the biotechnology company’s stock, valued at approximately $7,412,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Clearstead Advisors LLC boosted its holdings in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares during the period. Independent Advisor Alliance raised its stake in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares during the period. Florida Financial Advisors LLC lifted its position in shares of United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares in the last quarter. NDVR Inc. lifted its position in shares of United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30 shares in the last quarter. Finally, Principal Securities Inc. boosted its stake in shares of United Therapeutics by 4.7% in the fourth quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 31 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on UTHR. UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. HC Wainwright increased their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Royal Bank Of Canada lowered their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 8,750 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $538.15, for a total value of $4,708,812.50. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,158,119.40. This trade represents a 31.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $548.69, for a total transaction of $5,212,555.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,229,077.97. This trade represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 643,218 shares of company stock worth $363,705,304 over the last 90 days. Insiders own 8.60% of the company’s stock.

United Therapeutics Stock Down 1.2%

Shares of United Therapeutics stock opened at $543.39 on Friday. The business has a 50-day moving average price of $561.93 and a 200 day moving average price of $525.46. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The firm has a market cap of $23.07 billion, a P/E ratio of 20.06, a P/E/G ratio of 1.81 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the business earned $6.63 EPS. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 26.49 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.